

Publication of Kazuo Umezawa since 1990. Articles in Japanese are removed, so there are gaps in number.

1. K. Umezawa, T. Hori, H. Tajima, M. Imoto, K. Isshiki and T. Takeuchi: Inhibition of epidermal growth factor-induced DNA synthesis by tyrosine kinase inhibitors. FEBS Letters 260: 198-200, 1990.
2. M. Toi, H. Mukaida, T. Wada, N. Hirabayashi, T. Toge, T. Hori and K. Umezawa: Antineoplastic effect of erbstatin on human mammary and esophageal tumors in athymic mice. Eur. J. Cancer 26: 722-724, 1990.
3. M. Imoto, N. Shimura, H. Ui and K. Umezawa: Inhibition of EGF-induced phospholipase C activation in A 431 cells by erbstatin. Biochem. Biophys. Res. Commun. 173: 208-211, 1990.
4. H. Nishioka, T. Sawa, M. Hamada, N. Shimura, M. Imoto and K. Umezawa: Inhibition of phosphatidylinositol kinase by toyocamycin. J. Antibiot. 43: 1586-1589, 1990.
5. Y. Honma, J. Okabe-Kado, T. Kasukabe, M. Hozumi and K. Umezawa: Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells. Jpn. J. Cancer Res. 81: 1132-1136, 1990.
6. J. Pierre, S. Mousset, M. Pierre, K. Umezawa and A. Jacquemin-Sablon: Effect of erbstatin on EGF-mediated events in NIH-3T3 cells. J. Cell Pharm. 1: 8-11, 1990.
7. T. Onoda, K. Isshiki, T. Takeuchi, K. Tatsuta and K. Umezawa: Inhibition of tyrosine kinase and epidermal growth factor receptor internalization by lavendustin A methyl ester in cultured A431 cells. Drugs Exptl. Clin. Res. 16: 249-253, 1990.
8. S. Atsumi, K. Umezawa, H. Iinuma, H. Naganawa, H. Nakamura, Y. Iitaka and T. Takeuchi: Production, isolation and structure determination of a novel  $\beta$ -glucosidase inhibitor, cyclophellitol, from *Phellinus* sp. J. Antibiot. 43: 49-53, 1990.
9. S. Atsumi, H. Iinuma, C. Nosaka and K. Umezawa: Biological activities of

cyclophellitol. *J. Antibiot.* 43: 1579-1585, 1990.

10. K. Tatsuta, Y. Niwata, K. Umezawa, K. Toshima and M. Nakata: Enantiospecific total synthesis of a  $\beta$ -glucosidase inhibitor, cyclophellitol. *Tetrahedron Lett.* 31: 1171-1172, 1990.

14. P. H. Naccache, C. Gilbert, A. C. Caon, M. Gaudry, C. -K. Huang, V. A. Bonak, K. Umezawa and S. R. McColl: Selective inhibition of human neutrophil functional responsiveness by erbstatin, an inhibitor of tyrosine protein kinase. *Blood* 76: 2098-2104, 1990.

15. M. Imoto, K. Umezawa, Y. Takahashi, H. Naganawa, Y. Iitaka, H. Nakamura, Y. Koizumi, Y. Sasaki, M. Hamada, T. Sawa and T. Takeuchi: Isolation and structure determination of inostamycin, a novel inhibitor of phosphatidylinositol turnover. *J. Nat. Prod.* 53: 825-829, 1990.

16. K. Umezawa, K. Tanaka, T. Hori, S. Abe, R. Sekizawa and M. Imoto: Induction of morphological change by tyrosine kinase inhibitors in Rous sarcoma virus-transformed rat kidney cells. *FEBS Lett.* 279: 132-136, 1991.

17. M. Kawada, M. Imoto and K. Umezawa: Suppression of multidrug resistance by inostamycin in cultured human carcinoma KB cells. *J. Cell Pharmacol.* 2: 138-142, 1991.

18. M. Imoto, N. Johtoh and K. Umezawa: Inhibition by phosphatidylinositol turnover inhibitors of epidermal growth factor-induced rounding of A431 cells. *J. Cell Pharmacol.* 2: 49-53, 1991.

19. K. Umezawa and M. Imoto: Use of erbstatin as a protein-tyrosine kinase inhibitor. *Meth. Enzymol.* 201 : 379-385, 1991.

21. M. Imoto, N. Shimura and K. Umezawa: Inhibition of epidermal growth factor-induced activation of phospholipase C by psi-tectorigenin. *J. Antibiot.* 44: 915-917, 1991.

22. N. Takekura, W. Yasui, E. Kyo, K. Yoshida, T. Kameda, Y. Kitadai, K. Abe, K.

Umezawa and E. Tahara: Effects of tyrosine kinase inhibitor, erbstatin, on cell growth-factor/receptor gene expression in human gastric carcinoma cells. *Int. J. Cancer* 47: 938-942, 1991.

23. S. Nishiwaki, H. Fujiki, S. Yoshizawa, M. Suganuma, H. Furuya-Suguri, S. Okabe, M. Nakayasu, K. Okabe, H. Muratake, M. Natsume, K. Umezawa, S. Sakai and T. Sugimura: Pendolmycin, a new tumor promoter of the teleocidin A class on skin of CD-1 mice. *Jpn. J. Cancer Res.* 82: 779-783, 1991.

24. S. G. Withers and K. Umezawa: Cyclophellitol: a naturally occurring mechanism-based inhibitor of beta-glucosidases. *Biochem. Biophys. Res. Commun.* 177: 532-537, 1991.

27. M. Kawada and K. Umezawa: Long-lasting accumulation of vinblastine in inostamycin-treated multidrug-resistant KB cells. *Jpn. J. Cancer Res.* 82: 1160-1164, 1991.

28. H. Nishioka, T. Sawa, H. Nakamura, H. Iinuma, D. Ikeda, R. Sawa, H. Naganawa, C. Hayashi, M. Hamada, T. Takeuchi, Y. Iitaka and K. Umezawa: Isolation and structure determination of novel phosphatidylinositol kinase inhibitors, echiguanine A and B, from *Streptomyces sp.* *J. Nat. Prod.* 54: 1321-1325, 1991.

29. H. Nishioka, T. Sawa, K. Isshiki, Y. Takahashi, H. Naganawa, H. Matsuda, S. Hattori, M. Hamada, T. Takeuchi and K. Umezawa: Isolation and structure determination of a novel phosphatidylinositol turnover inhibitor, piericidin B1 N-oxide. *J. Antibiot.* 44: 1283-1285, 1991.

30. M. Makishima, Y. Honma, M. Hozumi, K. Sampi, M. Hattori, K. Umezawa and K. Motoyoshi: Effects of inhibitors of protein tyrosine kinase activity and /or phosphatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells. *Leukemia Res.* 15: 701-708, 1991.

32. T. Hori, T. Kondo, T. Tsuji, M. Imoto and K. Umezawa: Inhibition of tyrosine kinase and src oncogene functions by stable erbstatin analogues. *J. Antibiot.* 45: 280-282, 1992.

33. M. Kawada, S. Sumi, K. Umezawa, S. Inoue, T. Sawa and H. Seto: Circumvention of multidrug resistance in human carcinoma KB cells by polyether antibiotics. *J. Antibiot.* 45: 556-562, 1992.
34. N. Johtoh and K. Umezawa: Inhibition of EGF-induced cytoskeletal change in A431 cells by inhibitors of phosphatidylinositol turnover. *Drugs Exptl. Clin. Res.* 18: 1-7, 1992.
36. K. Tatsuta, Y. Niwata, K. Umezawa, K. Toshima and M. Nakata: Enantiospecific synthesis and biological evaluation of 1,6-epi-cyclophellitol. *J. Antibiot.* 44: 456-458, 1991.
37. K. Tatsuta, Y. Niwata, K. Umezawa, K. Toshima and M. Nakata: Synthesis and enzyme inhibiting activities of cyclophellitols. *Carbohydrate Res.* 222: 189-203, 1991.
38. K. Tatsuta, Y. Niwata, K. Umezawa, K. Toshima and M. Nakata: Total synthesis of glucosidase inhibitors, cyclophellitols. *Carbohydrate Res.* 222: 189-203, 1991.
40. M. Imoto, Y. Taniguchi and K. Umezawa: Inhibition of CDP-DG: inositol transferase by inostamycin. *J. Biochem.* 112: 299-302, 1992.
42. E. Ikoma, M. Naoi, T. Nagatsu and K. Umezawa: Induction of transient differentiation of rat pheochromocytoma PC12 cells by tyrosine kinase inhibitors. *Biogenic Amines* 9: 153-162, 1992.
43. Y. Tabata, M. Imoto and K. Umezawa: Biosynthetic preparation of radioactively labeled erbstatin. *J. Antibiot.* 45: 1382-1384, 1992.
44. S. Atsumi, C. Nosaka, H. Inuma and K. Umezawa: Inhibition of glucocerebrosidase and induction of neural abnormality by cyclophellitol in mice. *Arch. Biochem. Biophys.* 297: 362-367, 1992.
45. S. Bourgoin, P. E. Poubelle, N. W. Liao, K. Umezawa, P. Bougeat and P. H. Naccache: Granulocyte-macrophage colony-stimulating factor primes phospholipase D activity in human neutrophils in vitro : role of calcium, G-proteins and tyrosine kinases. *Cellular Signalling* 4: 487-500, 1992.

47. K. Umezawa: Microbial secondary metabolites and inhibition of oncogene product functions. in *Frontiers and New Horizons in Amino Acid Research*, K. Takai, ed., Elsevier, pp91-98, 1992.
48. K. Umezawa, D. Sugata, K. Yamashita, N. Johtoh and M. Shibuya: Inhibition of epidermal growth factor receptor functions by tyrosine kinase inhibitors. *FEBS Lett.* 314 : 289-292, 1992.
49. M. Imoto, I. Sujikai, H. Ui and K. Umezawa: Involvement of tyrosine kinase in growth factor-induced phospholipase C activation in NIH3T3 cells. *Biochim. Biophys. Acta* 1155: 188-192, 1993.
50. H. Kakeya, M. Imoto, Y. Tabata, J. Iwami, H. Matsumoto, K. Nakamura, T. Koyano and K. Umezawa: Isolation of a novel substrate-competitive tyrosine kinase inhibitor, desmal, from the plant *Desmos chinensis*. *FEBS Lett.* 320: 169-172, 1993.
51. H. Nishioka, T. Sawa, Y. Takahashi, H. Naganawa, M. Hamada, T. Takeuchi and K. Umezawa: Isolation and structure determination of novel phosphatidylinositol turnover inhibitors, piericidin B5 N-oxide, from *Streptomyces* sp. *J. Antibiot.* 46: 564-568, 1993.
52. S. Atsumi, C. Nosaka, H. Inuma and K. Umezawa: Accumulation of tissue glucosylsphingosine in Gaucher-like mouse induced by the glucosylceramidase inhibitor cyclophellitol. *Arch. Biochem. Biophys.* 304: 302-304, 1993.
53. D. Sugata, K. Yamashita and K. Umezawa: Inhibition of serum-induced M-phase progression by a tyrosine kinase inhibitor, erbstatin. *Biochem. Biophys. Res. Commun.* 194: 239-245, 1993.
54. Y. Watanabe, H. Kakeya, E. Ikoma and K. Umezawa: Induction of morphological and enzymic differentiation in rat pheochromocytoma PC12h cells by stable erbstatin analogues. *Drugs Exptl. Clin. Res.* 19: 1-6, 1993.
56. K. Umezawa, T. Aoyagi, W. Tanaka and T. Takeuchi: Low molecular-weight protease inhibitors of microbial origin. in W. Troll and A. Kennedy eds. *Protease*

Inhibitors as Cancer Chemopreventive Agents. Plenum Press, New York, pp131-139, 1993.

58. T. Hiramatsu, M. Imoto, T. Koyano and K. Umezawa: Induction of normal phenotypes in ras-transformed cells by damnacanthol from *Morinda citrifolia*.. Cancer Letters 73: 161-166, 1993.

59. S. Atsumi, C. Nosaka, Y. Ochi, H. Iinuma and K. Umezawa: Inhibition of experimental metastasis by an  $\alpha$ -glucosidase inhibitor, 1,6-epi-cyclophellitol. Cancer Res. 53: 4896-4899, 1993.

60. M. Imoto, H. Kakeya, T. Sawa, C. Hayashi, M. Hamada, T. Takeuchi and K. Umezawa: Dephostasin, a novel protein tyrosine phosphatase inhibitor produced by *Streptomyces*. I. Taxonomy, isolation, and characterization. J. Antibiot. 46: 1342-1346, 1993.

61. Y. Ochi, S. Atsumi, T. Aoyagi and K. Umezawa: Inhibition of tumour cell invasion in the Boyden chamber assay by a mannosidase inhibitor, mannostatin A. Anticancer Res. 13 :1421-1424, 1993.

63. H. Kakeya, M. Imoto, Y. Takahashi, H. Naganawa, T. Takeuchi and K. Umezawa: Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by *Streptomyces*. II. Structure determination. J. Antibiot. 46: 1716-1719, 1993.

64. E. K. Azuma, S. Kitagawa, A. Yuo, H. Mizoguchi, K. Umezawa, F. Takaku and M. Saito: Activation of the respiratory burst and tyrosine phosphorylation of proteins in human neutrophils : no direct relationship and involvement of protein kinase C-dependent and independent signaling pathways. Biochim. Biophys. Acta 1179: 213-223, 1993.

65. K. Umezawa: Oncogene function inhibitors of microbial origin. in V. P. Gullo, ed., The discovery of natural products with therapeutic potential. Butterworth-Heinemann, Boston, pp267-280, 1994.

66. M. Kawada, J. Tawara, T. Tsuji, Y. Honma, M. Hozumi, J. W. J. Wang and K. Umezawa: Inhibition of abl oncogene function by erbstatin analogues. Drugs. Exptl.

Clin. Res. 19: 235-241, 1993.

67. T. Watanabe, T. Takeuchi, M. Otsuka and K. Umezawa: Total synthesis of dephostatin, a novel protein tyrosine phosphatase inhibitor. J. Chem. Soc., Chem. Commun. 1994: 437-438.

68. H. Nishioka, M. Imoto, T. Imaoka, T. Sawa, T. Takeuchi and K. Umezawa: Antitumor effect of piericidin B1 N-oxide. J. Antibiot. 47: 447-452, 1994.

69. M. Imoto, Y. Taniguchi, H. Fujiwara and K. Umezawa: Enhancement of CDP-DG: inositol transferase activity in src- and erbB2-transformed cells. Exp. Cell Res. 212: 151-154, 1994.

70. K. Shimokado, T. Yokota, K. Umezawa, T. Sasaguri and J. Ogata: Protein tyrosine kinase inhibitors inhibit chemotaxis of vascular smooth muscle cells. Arteriosclerosis and Thrombosis 14: 973-981, 1994.

71. M. Imoto, T. Nakamura, S. Tanaka and K. Umezawa: Inhibition of T cell receptor-mediated signal transduction by erbstatin. Biosci. Biotech. Biochem. 58: 1700-1701, 1994.

72. S. Simizu, M. Imoto and K. Umezawa: Induction of apoptosis by erbstatin in mouse leukaemia L1210 cells. Biosci. Biotech. Biochem. 58 : 1549-1552, 1994.

73. J. Markovits, A. K. Larsen, E. Segal-Bendirdian, P. Fosse, J.-M. Saucier, A. Gazit, A. Levitzki, K. Umezawa and A. Jacquemin-Sablon: Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives. Biochem. Pharmacol. 48: 549-560, 1994.

74. C. Furihata, A. Yamakoshi, A. Hatta, M. Tatematsu, H. Iwata, K. Hayashi, K. Umezawa and T. Matsushima: Induction of c-fos and c-myc oncogene expression in the pyloric mucosa of rat stomach by N-methyl-N'-nitro-N-nitrosoguanidine and taurocholate. Cancer Lett. 83: 215-220, 1994.

75. Y. Watanabe, N. Shimada, T. Nagatsu and K. Umezawa: Inhibition of G protein-mediated differentiation of PC12 cells by an IMP dehydrogenase inhibitor,

oxanosine. Biogenic Amines 10: 509-517, 1994.

76. M. Imoto, T. Morii, A. Deguchi and K. Umezawa: Involvement of phosphatidylinositol synthesis in the regulation of S-phase induction. Exp. Cell Res. 215: 228-233, 1994.

77. N. Matsuda, S. Kageyama, A. Endo and K. Umezawa: Induction of normal phenotypes and potentiation of 5-fluorouracil by an HMG-CoA reductase inhibitor, compactin, in ras-transformed cells. Cellular Pharmacology 1: 219-223, 1994.

78. W. K. Arbotounou, K. Umezawa, A. Jacquemin-Sablon and J. Pierre: Inhibition by two lavendustins of the tyrosine kinase activity of pp60F527 in vitro and in intact cells. Eur. J. Pharmacol. 269: 1-8, 1994.

79. M. Kawada and K. Umezawa: Biosynthesis and radioisotope labeling of inostamycin. J. Nat. Prod. 57: 1266-1270, 1994.

80. K. Umezawa, T. Ohse, T. Yamamoto, T. Koyano and Y. Takahashi: Isolation of a new vinca alkaloid from the leaves of *Ervatamia microphylla* as an inhibitor of ras functions. Anticancer Res. 14: 2413-2418, 1994.

81. Y. Mizutani, S. Masuoka, M. Imoto, M. Kawada and K. Umezawa: Induction of erythroid differentiation in leukaemic K562 cells by an S-adenosylhomocysteine hydrolase inhibitor, aristeromycin. Biochem. Biophys. Res. Commun. 209: 25-30, 1995.

82. M. Kawada and K. Umezawa: Suppression of in vitro invasion of human fibrosarcoma cells by a leupeptin analogue inhibiting the urokinase-plasmin system. Biochem. Biophys. Res. Commun. 209: 25-30, 1995.

83. K. Umezawa: Screening of oncogene function inhibitors from microbial secondary metabolites. A. Rahman ed., Studies in Natural Products Chemistry, Vol. 15, Elsevier Science B. V. pp439-463, 1995.

85. K. Umezawa: Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Advan. Enzyme Regul. 35: 43-53, 1995.



86. H. Ui, M. Imoto and K. Umezawa: Inhibition of phosphatidylinositol-specific phospholipase C activity by fluvirucin B2. *J. Antibiot.* 48: 387-390, 1995.
87. K. Umezawa, S. Masuoka, T. Ohse, H. Naganawa, S. Kondo, Y. Ikeda, N. Kinoshita, M. Hamada, T. Sawa and T. Takeuchi: Isolation from *Streptomyces* of a novel naphthoquinone compound, naphthablin, that inhibits abl oncogene functions. *J. Antibiot.* 48: 604-607, 1995.
89. M. Kawada and K. Umezawa: Inostamycin, an inhibitor of P-glycoprotein function, interacts specifically with phosphatidylethanolamine. *Jpn. J. Cancer Res.* 86 : 873-878, 1995.
90. H. Ui, T. Miyake, H. Iinuma, M. Imoto, S. Hattori, M. Hamada, T. Takeuchi, S. Umezawa and K. Umezawa: A novel cyclic lipoundecapeptide, pholipeptin, isolated from *Pseudomonas sp.* *Tetrahedron Lett.* 36 : 7479-7480, 1995.
91. M. Imoto, S. Tanaka, A. Deguchi, A. Hayakawa and K. Umezawa: *In situ* inhibition of protein-tyrosine phosphatase by dephostatin. *Cellular Pharmacology* 2: 199-203, 1995.
92. K. Shimokado, K. Umezawa and J. Ogata: Tyrosine kinase inhibitors inhibit multiple steps of the cell cycle of vascular smooth muscle cells. *Exp. Cell Res.* 220: 266-273, 1995.
94. T. Watanabe, T. Takeuchi, M. Otsuka, S. Tanaka and K. Umezawa: Synthesis and protein tyrosine phosphatase inhibitory activity of dephostatin analogs. *J. Antibiot.* 48 : 1460-1466, 1995.
95. Y. Muraoka, R. Sekizawa, H. Nakamura, M. Tsuda, K. Umezawa and T. Takeuchi: Synthesis and stereochemistry of valinoctin A, a novel farnesyltransferase inhibitor from *Streptomyces sp.* *Peptide Chemistry* 1995: 149-151, 1996.
96. H. Kurata, S. Nishiyama, S. Yamamura, K. Kato, S. Fujiwara and K. Umezawa: First synthesis of enantiomerically pure carbocyclic oxanosine as a potential chemotherapeutic agent. *Bioorg. Med. Chem. Lett.* 6: 283-286, 1996.

97. N. Amino, T. Ohse, T. Koyano and K. Umezawa: Inhibition of cellular chemotactic invasion by a vinca alkaloid, conophylline. *Anticancer Res.* 16: 55-60, 1996.
98. R. Sekizawa, H. Iinuma, Y. Muraoka, H. Naganawa, N. Kinoshita, H. Nakamura, M. Hamada, T. Takeuchi and K. Umezawa: Isolation and synthesis of novel farnesyl protein transferase inhibitors, valinoctins A and B, from *Streptomyces* strain MJ858-NF3. *J. Nat. Prod.* 59: 232-236, 1996.
99. R. Sekizawa, H. Iinuma, H. Naganawa, M. Hamada, T. Takeuchi, J. Yamaizumi and K. Umezawa: Isolation of novel saquayamycins as inhibitors of farnesyl-protein transferase. *J. Antibiot.* 49: 487-490, 1996.
100. 梅澤一夫: シグナル伝達とアポトーシス。血液・免疫・腫瘍 1(3): 240-246, 1996.
101. S. Yoshida, A. Ota, K. Umezawa and T. Nagatsu: Dissociated release of tetrahydrobiopterin and nitric oxide by lipopolysaccharide from mouse neuroblastoma cells. *Neuroscience Lett.* 212: 135-138, 1996.
103. T. Ohse, S. Ohba, T. Yamamoto, T. Koyano and K. Umezawa: Cyclopentabenzofuran lignan protein synthesis inhibitors from *Aglaia odorata*. *J. Nat. Prod.* 59 : 650-652, 1996.
104. K. Umezawa, T. Taniguchi, M. Toi, T. Ohse, N. Tsutsumi, T. Yamamoto, T. Koyano and M. Ishizuka: Growth inhibition of K-Ras-expressing tumours by a new vinca alkaloid, conophylline, in nude mice. *Drugs Exptl. Clin. Res.* 22, 35-40, 1996.
105. M. Tsuda, Y. Muraoka, T. Takeuchi, R. Sekizawa and K. Umwzawa: Stereospecific synthesis of a novel farnesyl protein transferase inhibitor, valionoctin A and its analogue. *J. Antibiot.* 49: 1031-1035, 1996.
106. Y. Kikuchi, S. Nishiyama, S. Yamamura, K. Kato, S. Fujiwara, K. Umezawa and Y. Terada: Synthesis of C-oxetanosyl-thiazole and its carbocyclic analog nucleosides as potential chemotherapeutic agents. *Bioorg. Med. Chem. Lett.* 6: 1897-1900, 1996.

107. S. Simizu, M. Imoto, N. Masuda, M. Takada and K. Umezawa: Involvement of hydrogen peroxide production in erbstatin-induced apoptosis in human small cell lung carcinoma cells. *Cancer Res.* 56: 4978-4982, 1996.
109. A. Ota, S. Yoshida, T. Nomura, S. Matsui, Y. Hagino, K. Umezawa, S. Katoh and T. Nagatsu: Tetrahydrobiopterin biosynthesis enhanced by lipopolysaccharide stimulation in murine neuroblastoma cell line N1E-115. *J. Neurochem.* 67: 2540-2548, 1996.
110. A. Deguchi, M. Imoto and K. Umezawa: Inhibition of G1 cyclin expression in normal rat kidney cells by inostamysin, a phosphatidylinositol synthesis inhibitor. *J. Biochem.* 120: 1118-1122, 1996.
112. K. Sanpei, Y. Saito, M. Imoto, K. Umezawa and K. Katoh: Synthesis of ribofuranosyl glycosides of echiguanines A and B, inhibitors of phosphatidylinositol 4-kinase. *Bioorg. Med. Chem. Lett.* 6: 2487-2490, 1996.
113. K. Umezawa: Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants. G. Weber (ed.) *Advances of Enzyme Regulation* 36: 267-282, 1996.
114. H. Ui, T. Miyake, H. Inuma, M. Imoto, S. Hattori, M. Hamada, T. Takeuchi, S. Umezawa and K. Umezawa: Pholipeptin, a novel cyclic lipoundecapeptide from *Pseudomonas fluorescens*. *J. Org. Chem.* 62: 103-108, 1997.
115. A. Fukami, Y. Ikeda, S. Kondo, H. Naganawa, T. Takeuchi, S. Furuya, Y. Hirabayashi, K. Shimoike, S. Hosaka, Y. Watanabe and K. Umezawa: Akaterpin, a novel bioactive triterpene from the marine sponge *Callyspongia sp.* *Tetrahedron Lett.* 38: 1201-1202, 1997.
119. Y. Saito, K. Umezawa and K. Kato : Synthesis of echiguanine analogs and their ribofuranosyl glycosides that inhibit phosphatidylinositol 4-kinase. *Bioorg. Med. Chem. Lett.* 7 : 861-864, 1997.
120. K. Umezawa: Induction of cellular differentiation and apoptosis by signal

transduction inhibitors. *Advan. Enzyme Regul.* 37: 393-401, 1997.

121. S. Fujiwara, T. Watanabe, T. Nagatsu, J. Gohda, M. Imoto and K. Umezawa: Enhancement or induction of neurite formation by a protein tyrosine phosphatase inhibitor, 3, 4-dephostatin, in growth factor-treated PC12h cells. *Biochem. Biophys. Res. Commun.* 23: 213-217, 1997.

127. T. Liu, R. Shirai, T. Matsui, K. Umezawa and S. Iwasaki : Synthesis and biological activity of 5-[(2, 5-dihydroxybenzyl)amino] salicylic acid analogs as inhibitors of EGF receptor-associated protein tyrosine kinase. *Bioorg. Med. Chem. Lett.* 7: 365-368, 1997.

128. N. Kushida, S. Atsumi, T. Koyano and K. Umezawa: Induction of flat morphology in K-ras-transformed fibroblasts by lycorine, an alkaloid isolated from the tropical plant *Eucharis grandiflora*. *Drugs Exptl. Clin. Res.* 23: 151-155, 1997.

129. K. Umezawa, K. Nakazawa, T. Uemura, Y. Ikeda, S. Kondo, H. Naganawa, N. Kinoshita, H. Hashizume, M. Hamada, T. Takeuchi and S. Ohba: Polyoxypeptin isolated from *Streptomyces*: A bioactive cyclic depsipeptide containing the novel amino acid 3-hydroxy-3-methylproline. *Tetrahedron Lett.* 39: 1389-1392, 1998.

130. S. Simizu, K. Umezawa, M. Takada, N. Arber and M. Imoto: Induction of hydrogen peroxide production and bax expression by caspase-3(-like) proteases in tyrosine kinase inhibitor-induced apoptosis in human small cell lung carcinoma cells. *Exp. Cell Res.* 238: 197-203, 1998.

132. M. Imoto, K. Tanabe, S. Simizu, E. Tashiro, M. Takada and K. Umezawa: Inhibition of cyclin D1 expression and induction of apoptosis by inostamycin in small cell lung carcinoma cells. *Jpn. J. Cancer Res.* 89: 315-322, 1998.

133. Y. Han, C. G. Caday, K. Umezawa and A. Nanda: Preferential inhibition of glioblastoma cells with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl 2, 5-dihydroxycinnamate. *Oncol. Res.* 9: 581-587, 1997.

134. Y. Saito, K. Kato and K. Umezawa: Synthesis and structure-activity relationship

of ribofuranosyl echiguanine analogs as inhibitors of phosphatidylinositol 4-kinase. *Tetrahedron* 54: 4251-4266, 1998.

135. T. Watanabe, S. Kohzuma, T. Takeuchi, M. Otsuka and K. Umezawa: Total synthesis of ( $\pm$ )-aglaiastatin, a novel bioactive alkaloid. *J. Chem. Soc. Chem. Comm.* 1998: 1097-1098.

137. T. Watanabe, M. Imoto, H. Taniguchi, K. Kinoshita, Jr. and K. Umezawa: Synthesis of fluorescent substrates for protein tyrosine phosphatase assays. *Bioorg. Med. Chem. Lett.* 8: 1301-1302, 1998.

138. K. Umezawa: Signal transduction inhibitors from microorganisms and marine sponges. in S. Pandalai ed., *Research Developments in Agricultural & Food Chemistry*, Reseach Signpost, Trivandum, pp257-272, 1997.

139. T. Hiwasa, K. Kondo, T. Hishiki, S. Koshizawa, K. Umezawa and A. Nakagawara: GDNF-induced neurite formation was stimulated by protein kinase inhibitors and suppressed by Ras inhibitors. *Neuroscience Lett.* 238: 115-118, 1997.

140. R. Suginaka, R. Izui, J. Inoue, Y. Muraoka, K. Yamagachi, M. Otsuka and K. Umezawa: Induction of apoptosis in human pancreatic carcinoma cells by a synthetic bleomycin-like ligand. *Jpn. J. Cancer Res.* 89: 947-953, 1998.

141. E. Tashiro, S. Simizu, M. Takada, K. Umezawa and M. Imoto: Caspase-3 activation is not responsible for vinblastine-induced Bcl-2 phosphorylation and G2/M arrest in human small cell lung carcinoma Ms-1 cells. *Jpn. J. Cancer Res.* 89: 940-946, 1998.

142. S. Simizu, K. Tanabe, E. Tashiro, M. Takada, K. Umezawa and M. Imoto: Potentiation of paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma, Ms-1 cells. *Jpn. J. Cancer Res.* 89: 970-976, 1998.

143. S. Simizu, M. Takada, K. Umezawa, and M. Imoto: Requirement of caspase-3(-like) prtease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. *J. Biol. Chem.* 273: 26900-26907, 1998.

145. T. Hiwasa, Y. Arase, Z. Chen, K. Umezawa, H. Ito, N. Suzuki: Stimulation of ultraviolet-induced apoptosis of human fibroblast UVr-1 cells by tyrosine kinase inhibitors. FEBS Letters 444: 173-176, 1999.
146. M. Seemann, G. Zhai, K. Umezawa, and D. Cane: Pentalenene synthase. Histidine-309 is not required for catalytic activity. J. Am. Chem. Soc. 121: 591-592, 1999.
147. K. Umezawa, K. Nakazawa, Y. Ikeda, H. Naganawa, and S. Kondo: Polyoxypeptins A and B produced by *Streptomyces*: Apoptosis-inducing cyclic depsipeptides containing the novel amino acid (2S, 3R)-3-hydroxy-3-methylproline. J. Org. Chem. 64: 3034-3038, 1999.
148. T. Hiwasa, A. Takeda and K. Umezawa: Inhibition of thrombin and calpain by a ras inhibitor, damnacanthal. J. Biochem. Mol. Biol. & Biophys. 2: 311-316, 1999.
149. K. Umezawa and T. Watanabe: Synthetic study on protein tyrosine phosphatase inhibitor, dephostatin, and its stable analogs. Recent Res. Devel. Organic Chem. 3: 237-245, 1999.
150. K. Umezawa, K. Nakazawa, Y. Uchihata and M. Otsuka: Screening for inducers of apoptosis in apoptosis-resistant human carcinoma cells. Advan. Enzyme Regul. 39: 145-156, 1999.
151. Y. Saito, K. Kato and K. Umezawa: Synthesis and inhibitory activity against phosphatidylinositol 4-kinase of echiguanine analogs. Nucleosides & Nucleotides 18: 713-714, 1999.
154. S. Kumeda, A. Deguchi, M. Toi, S. Omura and K. Umezawa: Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells. Anticancer Res. 19: 3961-3968, 1999.
155. T. Irie, K. Kubushiro, K. Suzuki, K. Tsukazaki, K. Umezawa and S. Nozawa : Inhibition of attachment and chemotactic invasion of uterine endometrial cancer cells by a new vinca alkaloid, conophylline. Anticancer Res. 19: 3061-3066, 1999.

156. N. Kashihara, S. To-e, K. Nakamura, K. Umezawa, S. Yamamura and S. Nishiyama: Synthesis and biological activities of hapalosin derivatives with modification at the C12 position. *Bioorganic & Medicinal Chemistry Letters* 10: 101-103, 2000.
157. K. Umezawa, Y. Ikeda, Y. Uchihata, H. Naganawa and S. Kondo: Chloptosin, an apoptosis-inducing dimeric cyclohexapeptide produced by *Streptomyces*. *J. Org. Chem.* 65: 459-463, 2000.
158. T. Watanabe, T. Suzuki, Y. Umezawa, T. Takeuchi, M. Otsuka and K. Umezawa : Structure-activity relationship and rational design of 3,4-dephostatin derivatives as protein tyrosine phosphatase inhibitors. *Tetrahedron* 56: 741-752, 2000.
159. M. Itabashi, K. Segawa, Y. Ikeda, S. Kondo, H. Naganawa, T. Koyano and K. Umezawa : A new bioactive steroidal saponin, furcreastatin, from the plant *Furcraea foetida*. *Carbohydrate Res.* 323: 57-62, 2000.
160. C. Okudaira, Y. Ikeda, S. Kondo, S. Furuya, Y. Hirabayashi, T. Koyano, Y. Saito and K. Umezawa : Inhibition of acidic sphingomyelinase by xanthone compounds isolated from *Garcinia speciosa*. *J. Enzyme Inhibition* 15:129-138, 2000.
161. 梅澤一夫 : アポトーシスと抗癌剤。外科治療 82 (4): 497-498, 2000.
162. N. Endo, E. Tashiro, K. Umezawa, M. Kawada, Y. Uehara, Y. Doki, I. B. Weinstein and M. Imoto: Herbimycin A induces G1 arrest through accumulation of p27Kip1 in cyclin D1-overexpressing fibroblasts. *Biochem. and Biophys. Res. Commun.* 267: 54-58, 2000.
164. Y. Saito, M. Nakamura, T. Ohno, C. Chaicharoenpong, E. Ichikawa, S. Yamamura, K. Kato and K. Umezawa: Syntheses of oxanosine and carbocyclic oxanosine derivatives as anti-HIV agents. *J. Antibiot.* 53: 309-313, 2000.
165. T. Watanabe, Y. Shiraga, T. Takeuchi, M. Otsuka, and K. Umezawa: Formal total synthesis of aglaiastatin: Pd(0)-mediated construction of benzofurocyclopentane system. *Heterocycles* 53: 1051-1064, 2000.

167. N. Matsumoto, A. Ariga, S. To-e, H. Nakamura, N. Agata, S. Hirano, J. Inoue and K. Umezawa : Synthesis of NF- $\kappa$ B activation inhibitors derived from epoxyquinomicin C. *Bioorg. Med. Chem. Lett.* 10: 865-869, 2000.
168. N. Matsumoto, N. Agata, H. Kuboki, H. Inuma, T. Sawa, T. Takeuchi and K. Umezawa: Inhibition of rat embryo histidine decarboxylase by epoxyquinomicins. *J. Antibiot.* 53: 637-639, 2000.
170. M. Seki, M. Toi, K. Kobayashi, K. Shitara, K. Umezawa, B. K. Seon, M. Kan and J. Rhim: Differential behavior of VEGF receptor expression and response to TNP-470 in two immortalized human endothelial cell lines. *International Journal of Oncology* 17: 525-533, 2000.
171. S. Isonishi, A. Okamoto, K. Ochiai, Y. Saito and K. Umezawa: Phosphatidylinositol 4-kinase assay in ovarian carcinoma cells. in J. M. S. Bartlett ed., *Methods in Molecular Medicine. Vol. 39, Ovarian Cancer: Methods and Protocols.* Humana Press, pp607-610, 2000.
172. Y. Hashimoto, H. Jing, T. Niikura, Y. Ito, A. Hagiwara, K. Umezawa, Y. Abe, Y. Murayama and I. Nishimoto: Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases. *J. Neurosci.* 20: 8401-8409, 2000.
173. A. Hagiwara, Y. Hashimoto, T. Niikura, Y. Ito, K. Terashita, Y. Kita, I. Nishimoto and K. Umezawa: Neuronal cell apoptosis by a receptor-binding domain peptide of apoE4, not through low-density lipoprotein receptor-related protein. *Biochem. Biophys. Res. Commun.* 278: 633-639, 2000.
175. Y. Saito, M. Nakamura, T. Ohno, C. Chaicharoenpong, E. Ichikawa, S. Yamamura, K. Kato and K. Umezawa: Synthesis of sugar-modified derivatives of the unusual nucleoside oxanosine and its carbocyclic analogs as potential inhibitors of HIV. *J. Chem. Soc., Perkin Trans. 1* 2001: 298-304, 2001.
176. K. Umezawa, A. Ariga and N. Matsumoto: Review: Naturally occurring and synthetic inhibitors of NF- $\kappa$ B functions. *Anti-Cancer Drug Design* 15: 239-244, 2000.



178. O. Ohno, Y. Shima, Y. Ikeda, S. Kondo, K. Kato, M. Toi and K. Umezawa: Selective growth inhibition by sangivamycin of human umbilical vein endothelial cells. *International Journal of Oncology* 18: 1009-1015, 2001.
179. K. Umezawa, Y. Ikeda, O. Kawase, H. Naganawa and S. Kondo: Biosynthesis of polyoxypeptin A: novel amino acid 3-hydroxy-3-methylproline derived from isoleucine. *J. Chem. Soc., Perkin Trans. 1* 2001:1550-1553, 2001.
180. T. Suzuki, A. Hiroki, T. Watanabe, T. Yamashita, I. Takei and K. Umezawa: Potentiation of insulin-related signal transduction by a novel protein-tyrosine phosphatase inhibitor, Et-3,4-dephostatin, on cultured 3T3-L1 adipocytes. *J. Biol. Chem.* 276: 27511-27518, 2001.
181. M. Shiino, Y. Watanabe and K. Umezawa: Synthesis of N-substituted N-nitrosohydroxylamines as inhibitors of mushroom tyrosinase. *Bioorg. Med. Chem.* 9: 1233-1240, 2001.
183. K. Iikubo, Y. Ishikawa, N. Ando, K. Umezawa and S. Nishiyama: The first direct synthesis of  $\alpha$ -mangostin, a potent inhibitor of the acidic sphingomyelinase. *Tetrahedron Lett.* 43: 291-293, 2002
184. Y. Uchihata, N. Ando, Y. Ikeda, S. Kondo, M. Hamada and K. Umezawa: Isolation of a novel cyclic hexadepsipeptide pipalamycin from *Streptomyces* as an apoptosis-inducing agent. *J. Antibiot.* 55:1-5, 2002
185. A. Deguchi, K. Segawa, K. Hosaka, I. B. Weinstein and K. Umezawa: Overexpression of phosphatidylinositol synthase enhances growth and G1 progression in NIH3T3 cells. *Jpn. J. Cancer Res.* 93: 157-166, 2002.
187. A. Hiroki, H. Hatakeyama, M. Kawakami, T. Watanabe, I. Takei and K. Umezawa: Antidiabetic effect of a nitrosamine-free dephostatin analogue, methoxime-3,4-dephostatin, in db/db mice. *Biomed. Pharmacother.* 56: 173-178, 2002.
188. A. Ariga, J. Namekawa, N. Matsumoto, J. Inoue and K. Umezawa: Inhibition of

TNF- $\alpha$ -induced nuclear translocation and activation of NF- $\kappa$ B by dehydroxymethyl-epoxyquinomicin. *J. Biol. Chem.* 277: 27625-27630, 2002.

190. C. Chaicharoenpong and K. Umezawa: Minireview: Molecular design and biological activities of NF- $\kappa$ B inhibitors. *Mol. Cells* 14: 163-167, 2002.

191. C. Chaicharoenpong, K. Kato and K. Umezawa: Synthesis and structure-activity relationship of dehydroxymethylepoxyquinomicin analogues as inhibitors of NF- $\kappa$ B functions. *Bioorg. Med. Chem.* 10: 3933-3939, 2002.

192. K. Umezawa, Y. Ikeda, H. Naganawa and S. Kondo: Biosynthesis of the lipophylic side chain in the cyclic hexadepsipeptide antibiotic IC101. *J. Nat. Prod.* 65: 1953-1955, 2002.

193. E. Kikuchi, Y. Horiguchi, J. Nakashima, K. Kuroda, M. Oya, T. Ohigashi, N. Takahashi, Y. Shima, K. Umezawa and M. Murai: Suppression of hormone-refractory prostate cancer by a novel nuclear factor  $\kappa$ B inhibitor in nude mice. *Cancer Res.* 63: 107-110, 2003.

194. T. Hirano, M. Kizaki, K. Kato, F. Abe, N. Masuda and K. Umezawa: Enhancement of sensitivity by bestatin of acute promyelocytic leukemia NB4 cells to all-trans retinoic acid. *Leukemia Research* 26: 1097-1103, 2002.

195. K. Umezawa: Isolation of novel cyclic peptides from *Streptomyces* that induce apoptosis in apoptosis-resistant cancer cells. *Recent Res. Devel. Organic Chem.* 6: 421-429, 2002.

196. H. Takatsuna, H. Kato, J. Gohda, T. Akiyama, A. Moriya, Y. Okamoto, Y. Yamagata, M. Otsuka, K. Umezawa, K. Semba and J. Inoue: Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase 1 (IRAK-1) in IL-1 receptor signaling. *J. Biol. Chem.* 278: 12144-12150, 2003.

197. A. Miyajima, T. Kosaka, K. Seta, T. Asano, K. Umezawa and M. Hayakawa: Novel NF- $\kappa$ B activation inhibitor prevents inflammatory injury in unilateral urethral obstruction. *J. Urol.* 169: 1559-1563, 2003.

198. A. Hamasaki, H. Naka, F. Tamanoi, K. Umezawa and M. Otsuka: A novel metal-chelating inhibitor of protein farnesyltransferase. *Bioorg. Med. Chem. Lett.* 13: 1523-1526, 2003.
200. K. Umezawa, M. Kawakami and T. Watanabe: Molecular design and biological activities of protein-tyrosine phosphatase inhibitors. *Therapeutics & Pharmacology* 99: 15-24, 2003.
201. M. Shiino, Y. Watanabe and K. Umezawa: Synthesis and tyrosinase inhibitory activity of novel N-hydroxybenzyl-N-nitrosohydroxylamines. *Bioorg. Med. Chem.* 31: 129-135, 2003.
202. C. Chaicharoenpong, K. Kato and K. Umezawa: Preparation of radioactively labeled dehydroxymethyl-epoxyquinomicin, an NF- $\kappa$ B inhibitor. *Drugs Exptl. Clin. Res.* 29: 1-3, 2003.
203. K. Toshima, T. Kimura, R. Takano, T. Ozawa, A. Ariga, Y. Shima, K. Umezawa and S. Matsumura: Molecular design, chemical synthesis and biological evaluation of quinoxaline-carbohydrate hybrids as novel and selective photo-induced DNA cleaving and cytotoxic agents. *Tetrahedron* 59: 7057-7066, 2003.
204. H. Prinz, Y. Ishii, T. Hirano, T. Stoiber, J. A. C. Gomez, P. Schmidt, H. Duessmann, A. M. Burger, J. H. M. Prehn, E. G. Guenther, E. Unger and K. Umezawa: Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents-Synthesis, antiproliferative activity and inhibition of tubulin polymerization. *J. Med. Chem.* 46: 3382-3394, 2003.
205. M. Hamada, K. Iikubo, Y. Ishikawa, A. Ikeda, K. Umezawa and S. Nishiyama: Biological activities of  $\alpha$ -mangostin derivatives against acidic sphingomyelinase. *Bioorg. Med. Chem. Lett.* 13: 3151-3153, 2003.
206. J. Gohda, J. Inoue and K. Umezawa: Down-regulation of TNF receptors by conophylline in human T-cell leukemia cells. *Int. J. Oncol.* 23: 1373-1379, 2003.
207. K. Umezawa, A. Hiroki, M. Kawakami, H. Naka, I. Takei, T. Ogata, I. Kojima, T.

Koyano, T. Kowithayakorn, H. S. Pang and T. S. Kam: Induction of insulin production in rat pancreatic acinar carcinoma cells by conophylline. *Biomed. Pharmacother.* 57: 341-350, 2003.

209. Y. Horiguchi, K. Kuroda, J. Nakashima, M. Murai and K. Umezawa: Antitumor effect of a novel nuclear factor- $\kappa$ B activation inhibitor in bladder cancer cells. *Expert Rev. Anticancer Ther.* 3: 793-798, 2003.

210. S. Atsumi, A. Nagasawa, T. Koyano, T. Kowithayakorn and K. Umezawa: Suppression of TGF- $\beta$  signaling by conophylline via upregulation of c-Jun expression. *Cell. Mol. Life Sci.* 60: 2516-2525, 2003.

211. M. Murata, K. Midorikawa, M. Koh, K. Umezawa and S. Kawanishi: Genistein and daizein induce cell proliferation and their metabolites cause oxidative DNA damage in relation to isoflavone-induced cancer of estrogen-sensitive organs. *Biochemistry* 43: 2569-2577, 2004.

212. Y. Suzuki, C. Sugiyama, O. Ohno and K. Umezawa: Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF- $\kappa$ B inhibitor. *Tetrahedron* 60: 7061-7066, 2004.

213. O. Ohno, Y. Ikeda, R. Sawa, M. Igarashi, N. Kinoshita, Y. Suzuki, K. Miyake, and K. Umezawa: Isolation of heptadepsin, a novel bacterial cyclic depsipeptide that inhibits lipopolysaccharide activity. *Chemistry & Biology* 11: 1059-1070, 2004.

214. T. Ogata, L. Li, S. Yamada, Y. Yamamoto, Y. Tanaka, I. Takei, K. Umezawa and I. Kojima: Promotion of b cell differentiation by conophylline in fetal and neonatal rat pancreas. *Diabetes* 53: 2596-2602, 2004.

216. H. Takatsuna and K. Umezawa: Screening of bioactive metabolites for pancreatic regeneration chemotherapy. *Biomed. Pharmacother.* 58:610-613, 2004.

217. H. Ohgawara, K. Edamura, M. Kawakami and K. Umezawa: Diabetes mellitus: rational basis, clinical approach and future therapy. *Biomed. Pharmacother.* 58: 605-609, 2004.

218. D. V. Starenki, H. Namba, V. A. Saenko, A. Ohtsuru, S. Maeda, K. Umezawa and S. Yamashita: Induction of thyroid cancer cell apoptosis by a novel nuclear factor kappaB inhibitor, DHMEQ. Clin. Cancer Res. 10: 6821-6829, 2004.
219. M. Fujii, K. Umezawa and A. Arata: Dopaminergic effects on respiratory rhythm generation in rat brainstem-spinal cord preparation. Neuroscience Res. 50:355-359, 2004.
220. G. Matsumoto, J. Namekawa, M. Muta, T. Nakamura, H. Bando, K. Tohyama, M. Toi and K. Umezawa: Targeting of NF- $\kappa$ B pathways by DHMEQ, a novel inhibitor of breast carcinomas: Anti-tumor and anti-angiogenic activity *in vivo*. Clin. Cancer Res. 11: 1287-1293, 2005.
221. M. Nakamura, T. Ogawa, A. Yokono, S. Nakamori, T. Ohno and K. Umezawa: Synergistic antiviral effect of oxanosine and ddI against human immunodeficiency virus. Biomed. Pharmacother. 59: 47-50, 2005.
222. M. Watanabe, M. Z. Dewan, T. Okamura, M. Sasaki, K. Itoh, M. Higashihara, H. Mizoguchi, M. Honda, T. Sata, T. Watanabe, N. Yamamoto, K. Umezawa and R. Horie: A novel NF- $\kappa$ B inhibitor DHMEQ selectively targets constitutive NF- $\kappa$ B activity and induces apoptosis of multiple myeloma cells *in vitro* and *in vivo*. Int. J. Cancer 114: 32-38, 2005.
223. D. Kamiya, Y. Uchihata, E. Ichikawa, K. Kato and K. Umezawa: Reversal of drug resistance by COTC based on intracellular glutathione and glyoxalase I. Biorg. Med. Chem. Lett. 15:1111-1114, 2005.
224. H. Takatsuna, M. Asagiri, T. Kubota, K. Oka, T. Osada, C. Sugiyama, H. Saito, K. Aoki, K. Ohya, H. Takayanagi and K. Umezawa: Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF- $\kappa$ B inhibitor, through downregulation of NFATc1. J. Bone Mineral Res. 20: 653-661, 2005.
225. H. Takatsuna, S. Morita, T. Nagatsu, M. Sawada and K. Umezawa: Inhibition of inflammatory cytokine secretion from mouse microglia cells by DHMEQ, an NF- $\kappa$ B inhibitor. Biomed. Pharmacother. 59: 318-322, 2005.

226. O. Ohno, Y. Shima, Y. Ikeda, Y. Kawai, K. Sakurai, K. Watanabe, and K. Umezawa: Inhibition of cellular adhesion in human umbilical vein endothelial cells by NF- $\kappa$ B inhibitor DHMEQ under flow. *Oncology Res.* 15: 189-198, 2005.
227. H. Tatetsu, Y. Okuno, M. Nakamura, F. Matsuno, T. Sonoki, I. Taniguchi, S. Umeda, K. Umezawa, H. Mitsuya and H. Hata: A novel nuclear factor kappa B inhibitor induced apoptosis of multiple myeloma cells. *Mol. Cancer Ther.* 4: 1114-1120, 2005.
228. K. Wakamatsu, T. Nanki, N. Miyasaka, K. Umezawa and T. Kubota: Effect of a small molecule inhibitor of nuclear factor- $\kappa$ B nuclear translocation in a murine model of arthritis and cultured human synovial cells. *Arthritis Research & Therapy* 7: 1348-1359, 2005.
229. G. Matsumoto, M. Muta, K. Umezawa, T. Suzuki, K. Mitsumi, K. Tsuruta, A. Okamoto and M. Toi: Enhancement of the caspase-independent apoptotic sensitivity of pancreatic cancer cells by DHMEQ, an NF- $\kappa$ B inhibitor. *Int. J. Oncology* 27: 1247-1255, 2005.
230. M. Watanabe, T. Ohsugi, M. Shoda, T. Ishida, S. Aizawa, M. Maruyama-Nagai, A. Utsunomiya, S. Koga, Y. Yamada, S. Kamihira, A. Okayama, H. Kikuchi, K. Uozumi, K. Yamaguchi, M. Higashihara, K. Umezawa, T. Watanabe and R. Horie.: Dual targeting of transformed and untransformed HTLV-1-infected T-cells by DHMEQ, a potent and selective inhibitor of NF- $\kappa$ B, as a strategy for chemoprevention and therapy of adult T cell leukemia. *Blood* 106: 2462-2471, 2005.
231. M. Watanabe, M. Sasaki, K. Itoh, M. Higashihara, K. Umezawa, M. E. Kadin, L. J. Abraham, T. Watanabe and R. Horie: JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and Reed-Sternberg cells of Hodgkin lymphoma. *Cancer Res.* 65: 7628-7634, 2005.
232. K. Kuroda, Y. Horiguchi, J. Nakashima, E. Kikuchi, K. Kanao, A. Miyajima, T. Ohigashi, K. Umezawa and M. Murai: Prevention of cancer cachexia by a novel nuclear factor  $\kappa$ B inhibitor in prostate cancer. *Clin. Cancer Res.* 11: 5590-5594, 2005.

233. T. Ohsugi, R. Horie, T. Kumasaka, A. Ishida, T. Ishida, K. Yamaguchi, T. Watanabe, K. Umezawa and T. Urano: In vivo antitumor activity of the NF- $\kappa$ B inhibitor dehydroxymethyl-epoxyquinomicin in a mouse model of adult T-cell leukemia. *Carcinogenesis* 26: 1382-1388, 2005.
234. T. Ohsugi, T. Kumasaka, A. Ishida, T. Ishida, R. Horie, T. Watanabe, K. Umezawa and K. Yamaguchi: In vitro and in vivo antitumor activity of the NF-kappa B inhibitor DHMEQ in the human T-cell leukemia virus type I-infected cell line, HUT-102. *Leuk. Res.* 30:90-97, 2006.
235. T. Takahashi, O. Ohno, Y. Ikeda, R. Sawa, Y. Homma, M. Igarashi, K. Umezawa: Inhibition of lipopolysaccharide activity by a bacterial cyclic lipopeptide surfactin. *J. Antibiot.* 59: 35-43, 2006.
236. C. Culmsee, N. Gerling, S. Landshamer, B. Rickerts, H.-J. Duchstein, K. Umezawa, S. Klumpp and J. Krieglstein: Nitric oxide donors induce neurotrophin-like survival signaling and protect neurons against apoptosis. *Molecular Pharmacology* 68:1006-1017, 2005.
237. M. Fujii, K. Umezawa and A. Arata: Dopamine desynchronizes the pace-making neuronal activity of rat respiratory rhythm generation. *Eur. J. Neurosci.* 23: 1015-1027, 2006.
238. I. Kojima and K. Umezawa: Conophylline: A novel differentiation inducer for pancreatic  $\beta$  cells. *International Journal of Biochemistry & Cell Biology* 38: 923-930, 2006.
239. A. Sato, M. Oya, K. Ito, R. Mizuno, Y. Horiguchi, K. Umezawa, M. Hayakawa and M. Murai: Survivin associates with cell proliferation in renal cancer cells: Regulation of surviving expression by insulin-like growth factor-1, interferon- $\gamma$  and a novel NF- $\kappa$ B inhibitor. *Int. J. Oncology* 28: 841-846, 2006.
241. R. Horie, M. Watanabe, T. Okamura, M. Taira, M. Shoda, T. Motoji, A. Utsunomiya, T. Watanabe, M. Higashihara and K. Umezawa: DHMEQ, a new NF- $\kappa$ B inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. *Leukemia* 20: 800-806, 2006.

242. R. Horie, T Watanabe and K. Umezawa: Blocking NF- $\kappa$ B as a potential strategy to treat adult T-cell leukemia/lymphoma. *Drug News Perspect.* 19: 201-209, 2006.
244. M. Fujii, K. Umezawa and A. Arata: Adrenaline contributes to prenatal respiratory maturation in rat medulla-spinal cord preparation. *Brain Res.* 1090: 45-50, 2006.
246. K. Umezawa: Inhibition of tumor growth by NF- $\kappa$ B inhibitors. *Cancer Science* 97: 990-995, 2006.
247. E. Suzuki and K. Umezawa: Inhibition of macrophage activation and phagocytosis by a novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin. *Biomed. Pharmacother.* 60: 578-586, 2006.
248. Z. Wang, M. Igarashi, Y. Ikeda, R. Horie and K. Umezawa: Inhibition of NFkappa B activation by 9-methylstreptimidone isolated from *Streptomyces*. *Heterocycles* 69: 377-383, 2006.
249. H. Ruan, M. Masuda, A. Ito, K. Umezawa, T. Nakashima, R. Yasumatsu, Y. Kuratomi, T. Yamamoto, I. B. Weinstein and S. Komune: Effects of a novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), on growth, apoptosis, gene expression, and chemosensitivity in head and neck squamous cell carcinoma cell lines. *Head & Neck* 2006:158-164.
250. N. Komura, Y. Ikeda, N. Masuda, Y. Umezawa, K. Ito, M. Kizaki and K. Umezawa: Designed ATRA analogue active against ATRA-resistant acute promyelocytic leukemia cells having a single nucleotide substitution in their retinoic acid receptor. *Leuk. Res.* 31: 301-313, 2007.
251. R. Kitamura, T. Ogata, Y. Tanaka, K. Motoyoshi, M. Seno, I. Takei, K. Umezawa and I. Kojima: Conophylline and betacellulin- $\delta$ 4: an effective combination of differentiation factors for pancreatic  $\beta$  cells. *Endocrine J.* 54: 255-264, 2007.
252. M. Watanabe, M. Z. Dewan, M. Taira, M. Shoda, M. Honda, T. Sata, M. Higashihara, M. E. Kadin, T. Watanabe, N. Yamamoto, K. Umezawa and R. Horie:



I $\kappa$ B $\alpha$  independent induction of NF- $\kappa$ B and its inhibition by DHMEQ in Hodgkin/Reed-Sternberg cells. *Laboratory Investigation* 87: 372-382, 2007.

253. A. Katsman, K. Umezawa and B. Bonavida: Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent. *Drug Resistance Updates* 10: 1-12, 2007.

254. I. Palona, H. Namba, N. Mitsutake, D. Starenki, A. Podtcheko, I. Sedliarou, A. Ohtsuru, V. Saenko, Y. Nagayama, K. Umezawa and S. Yamashita: BRAFV600E promotes invasiveness of thyroid cancer cells through NF- $\kappa$ B activation. *Endocrinology* 147:5699-5707, 2006.

255. S. Ueki, K. Yamashita, T. Aoyagi, S. Haga, T. Suzuki, T. Itoh, M. Taniguchi, T. Shimamura, H. Furukawa, M. Ozaki, K. Umezawa and S. Todo: Control of allograft rejection by applying a novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin. *Transplantation*, 82: 1720-1727, 2006.

256. N. Nagai, Y. Oike, K. Izumi-Nagai, T. Koto, S. Satofuka, Y. Ozawa, K. Yamashiro, M. Inoue, K. Tsubota, K. Umezawa and S. Ishida: Suppression of diabetes-induced retinal inflammation by blocking angiotensin II type 1 receptor or its downstream NF- $\kappa$ B pathway. *Investigative Ophthalmology and Visual Science* 48: 4342-4350, 2007.

257. N. Kimura, Y. Miyakawa, K. Kohmura, K. Umezawa, Y. Ikeda and M. Kizaki: Targeting NF- $\kappa$ B and induction of apoptosis by novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ) in Burkitt lymphoma cells. *Leukemia Research*, 31: 1529-1535, 2007.

259. E. Suzuki, K. Umezawa and B. Bonavida: Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: Involvement in chemosensitization to drug-induced apoptosis. *Oncogene* 26: 6184-6189, 2007.

260. N. Komura, M. Asakawa, K. Umezawa and K. Segawa: Tyrosine kinase inhibitor methyl-2,5-dihydroxycinnamate induces PML nuclear body formation and apoptosis in tumor cells. *Exp. Cell Res.* 313: 2753-2765, 2007.

261. T. Ohsugi, T. Kumasaka, S. Okada, T. Ishida, K. Yamaguchi, R. Horie, T.

Watanabe, and K. Umezawa: Dehydroxymethylepoxyquinomicin (DHMEQ) therapy reduces tumor formation in mice inoculated with Tax-deficient adult T-cell leukemia–derived cell lines. *Cancer Letters* 257: 206-215, 2007.

262. Y. N. Kimura, K. Watari, A. Fotovati1, F. Hosoi1, K. Yasumoto, H. Izumi, K. Kohno, K. Umezawa, H. Iguchi, K. Shirouzu, S. Takamori, M. Kuwano and M. Ono: Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. *Cancer Science* 98: 2009-2018, 2007.

263. Y. Komi, O. Ohno, Y. Suzuki, M. Shimamura, K. Shimokado, K. Umezawa and S. Kojima: Inhibition of tumor angiogenesis by targeting endothelial ATP synthase with sangivamycin. *Japan Journal of Clinical Oncology*, 37:867-873, 2007.

265. T. Kubota, M. Hoshino, K. Aoki, K. Ohya, Y. Komano, T. Nanki, N. Miyasaka and K. Umezawa: NF- $\kappa$ B inhibitor DHMEQ suppresses osteoclastogenesis and expression of NFATc1 in mouse arthritis without affecting expression of RANCL, OPG or M-CSF. *Arthritis Research & Therapy* <http://arthritis-research.com/content/9/5/R97>, 2007.

266. S. Baritaki, E. Suzuki, K. Umezawa, D. A. Spandidos, J. Berenson, T. R. Daniels, M. L. Penichet, A. R. Jazirehi, M. Palladino and B. Bonavida: Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. *J. Immunol.* 180: 6199-6210, 2008.

267. Y. Saisho, H. Hirose, C. Horimai, K. Miyashita, I. Takei, K. Umezawa and H. Itoh: Effects of DHMEQ, a novel nuclear factor- $\kappa$ B inhibitor on beta cell dysfunction in INS cells. *Endocrine J.* 55: 433-438, 2008.

268. E. Hisanaga, K.-Y. Park, S. Yamada, H. Hashimoto, T. Takeuchi, M. Mori, M. Seno, K. Umezawa, I. Takei and I. Kojima: A simple method to induce differentiation of murine bone marrow mesenchymal cells to insulin-producing cells using conophylline and betacellulin-delta4. *Endocrine J.* 55: 535-543, 2008.

269. A. Miyake, Z. Dewan, T. Ishida, M. Watanabe, M. Honda, T. Sata, N. Yamamoto, K. Umezawa, T. Watanabe and R. Horie: Induction of apoptosis in Epstein-Barr

virus-infected B-lymphocytes by the NF- $\kappa$ B inhibitor DHMEQ. *Microbes and Infection* 10: 748-756, 2008.

270. K. Izumi-Nagai, N. Nagai, K. Ohgami, S. Satofuka, Y. Ozawa, K. Tsubota, K. Umezawa, S. Ohno, Y. Oike and S. Ishida: Macular pigment lutein is anti-inflammatory in preventing choroidal neovascularization. *Arterioscler. Thromb. Vasc. Biol.*, *Arterioscler Thromb Vasc Biol.* 2007 Dec (12): 2555-2562, 2007.

271. T. Kosaka, A. Miyajima, E. Kikuchi, Y. Horiguchi, K. Umezawa, T. Ohigashi, J. Nakashima, T. Asano and M. Oya: The novel NF- $\kappa$ B activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats. *Nephron Exp. Nephrol.* 110: e17–e24, 2008.

272. T. Suzuki, K. Yamashita, W. Jomen, S. Ueki, T. Aoyagi, M. Fukai, H. Furukawa, K. Umezawa, M. Ozaki and S. Todo: The novel NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin, prevents local and remote organ injury following intestinal ischemia/reperfusion in rats. *J. Surg. Res.* 149: 69-75, 2008.

274. M. Watanabe, M. Nakashima, T. Togano, M. Higashihara, T. Watanabe, K. Umezawa and R. Horie: Identification of the RelA domain responsible for action of a new NF- $\kappa$ B inhibitor DHMEQ. *Biochem. Biophys. Res. Commun.* 376: 310-314, 2008.

275. C. Nishioka, T. Ikezoe, Y. Jing, K. Umezawa and A. Yokoyama: DHMEQ, a novel nuclear factor-kappaB inhibitor, induces selective depletion of alloreactive or phytohaemagglutinin-stimulated peripheral blood mononuclear cells, decreases production of T helper type 1 cytokines, and blocks maturation of dendritic cells. *Immunology* 124: 198-205, 2008.

276. E. Suzuki, C. Sugiyama and K. Umezawa: Inhibition of inflammatory mediator secretion by (-)-DHMEQ in mouse bone marrow-derived macrophages. *Biomed. Pharmacother.* 63: 351-358, 2009.

277. K. Horiuchi, H. Morioka, K. Nishimoto, M. Susa, R. Nakayama, A. Kawai, H. Sonobe, H. Takaishi, T. Ozaki, H. Yabe, K. Umezawa, Y. Toyama: Growth suppression and apoptosis induction in synovial sarcoma cell lines by a novel NF- $\kappa$ B inhibitor, Dehydroxymethylepoxyquinomicin (DHMEQ). *Cancer Letters* 272: 336-344, 2008.

278. M. I. Vega, M. Martinez-Paniagua, A. R. Jazirehi, S. Huerta-Yepez, K. Umezawa, O. Martinez-Maza and B. Bonavida: The NF- $\kappa$ B inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. *Leukemia and Lymphoma* 49-1982-1994, 2008.
281. M. Tachibana, C. Matsui, Y. Takeuchi, E. Suzuki and K. Umezawa: Inhibition of NF-kappa B activation by penicillic acid and dihydropenicillic acid isolated from fungi. *Heterocycles* 76: 1561-1569, 2008.
282. M. Yamamoto, R. Horie, M. Takeiri, I. Kozawa and K. Umezawa: Inactivation of nuclear factor kappa B components by covalent binding of (-)-dehydroxymethylepoxyquinomicin to specific cysteine residues. *J. Med. Chem.*, 51: 5780-5788, 2008.
283. E. Watanabe, N. Mochizuki, H. Ajima, K. Ohno, M. Shiino, K. Umezawa, M. Fukai, M. Ozaki, H. Furukawa, S. Todo, S. Kishino: A simple and reliable method for determining plasma concentration of dehydroxymethylepoxyquinomicin by high performance liquid chromatography with mass spectrometry. *J. Chromatography B* 871: 32-36, 2008.
284. B. Bonavida, A. R. Jazirehi, M. I. Vega, S. Huerta-Yepez,, K. Umezawa and E. Suzuki: Chemo-immunosensitization of resistant B-NHL as a result of rituximab (anti-CD20 mAb)-mediated inhibition of cell survival signaling pathways. in B. Bonavida (editor) *Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy*, pp29-40, Springer, 2008.
285. S. Makino, N. Mitsutake, M. Nakashima, V. A. Saenko, A. Ohtsuru, K. Umezawa, K. Tanaka, A. Hirano, S. Yamashita: DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. *J. Dermatol. Sci.* 51: 171-180, 2008.
286. Z. Meng, N. Mitsutake, M. Nakashima, D. Starenki, M. Matsuse, S. Takakura, H. Namba, V. Saenko, K. Umezawa, A. Ohtsuru, S. Yamashita: Dehydroxymethylepoxyquinomicin, a novel nuclear Factor-kappaB inhibitor, enhances antitumor activity of taxanes in anaplastic thyroid cancer cells. *Endocrinology* 149:

5357-5365, 2008.

287. Y. Ishikawa, M. Tachibana, C. Matsui, R. Obata, K. Umezawa and S. Nishiyama: Synthesis and biological evaluation on novel analogs of 9-methyl-streptimidone, an inhibitor of NF- $\kappa$ B. *Bioorg. Med. Chem. Lett.* 19: 1726-1728, 2009.

289. E. Suzuki, Y. Ninomiya and K. Umezawa: Induction of histidine decarboxylase in macrophages inhibited by the novel NF-kappa B inhibitor (-)-DHMEQ. *Biochem. Biophys. Res. Commun.* 379: 379-383, 2009.

290. E. Suzuki, H. Ogura, K. Kato, I. Takei, Y. Kabe, Hiroshi Handa and K. Umezawa: Preparation of conophylline affinity nanobeads and identification of a target protein. *Bioorg. Med. Chem.* 17: 6185-6195, 2009.

291. J. Inumaru, O. Nagano, E. Takahashi, T. Ishimoto, S. Nakamura, Y. Suzuki, S. Niwa, K. Umezawa, H. Tanihara and H. Saya: Molecular mechanisms regulating dissociation of cell-cell junction of epithelial cells by oxidative stress. *Genes Cells* 14: 706-716, 2009.

292. N. Dabaghmanesh, A. Matsubara, A. Miyake, K. Nakano, T. Ishida, H. Katano, R. Horie, K. Umezawa and T. Watanabe: Transient inhibition of NF- $\kappa$ B by DHMEQ induces cell death of primary effusion lymphoma without HHV-8 reactivation. *Cancer Science* 100: 737-746, 2009.

293. I. Kozawa, K. Kato, T. Teruya, K. Suenaga and K. Umezawa: Unusual intramolecular N>O acyl group migration occurring during conjugation of (-)-DHMEQ with cysteine. *Bioorg. Med. Chem. Lett.* 19: 5380-5382, 2009.

294. T. Saitoh, E. Suzuki, A. Takasugi, R. Obata, Y. Ishikawa, K. Umezawa and S. Nishiyama: Efficient synthesis of ( $\pm$ )-parasitenone, a novel inhibitor of NF- $\kappa$ B. *Bioorg. Med. Chem. Lett.* 19: 5383-5386, 2009.

295. K. Toshima, S. Tanimoto, K. Tsumura, K. Umezawa and D. Takahashi: Target-selective degradation of cancer-related proteins by novel photosensitizers for molecular-targeted photodynamic therapy. (Review article) *Cancer Science* 100: 1581-1584, 2009.

296. T. Kubota, Y. Fukuya, R. Hashimoto, T. Kanda, H. Suzuki, Y. Okamura, T. Nanki, N. Miyasaka and K. Umezawa: Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome: an attractive target for the NF- $\kappa$ B-specific inhibitor DHMEQ. *Ann. N. Y. Acad. Sci.* 1173: 137-145, 2009.
297. N. Tsukamoto, S. Okada, Y. Onami, Y. Sasaki, K. Umezawa and Y. Kawakami: Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells. *Clin. Cancer Res.* 15: 5733-5743, 2009.
300. M. Hamada, Y. Inami, Y. Nagai, T. Higashi, M. Shoji, S. Ogawa, K. Umezawa, T. Sugai: Enzyme-catalyzed resolution of 3,8-dioxatricyclo[3.2.1.0<sup>2,4</sup>]octane-6-carboxylic esters and the application to the synthesis of 3-epishikimic acid. *Tetrahedron: Asymmetry* 20: 2105-2111, 2009.
301. T. Togano, M. Sasaki, M. Watanabe, M. Nakashima, T. Tsuruo, K. Umezawa, M. Higashihara, T. Watanabe and R. Horie: Induction of oncogene addiction shift to NF- $\kappa$ B by camptothecin in solid tumor cells. *Biochem. Biophys. Res. Commun.* 390: 60-64, 2009.
302. M. Fujii, I. Takei and K. Umezawa: Antidiabetic effect of plant extract containing conophylline by oral administration in streptozotocin-treated and Goto-Kakizaki rats. *Biomedicine & Pharmacotherapy* 63: 710-716, 2009.
303. T. Chiba, Y. Kondo, S. Shinozaki, E. Kaneko, A. Ishigami, N. Maruyama, K. Umezawa and K. Shimokado: A selective NF- $\kappa$ B inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. *J. Atherosclerosis Thrombosis* 13: 308-313, 2006.
304. N. Lampiasi, A. Azzolina, N. D'Alessandro, K. Umezawa, J. A. McCubrey, G. Montalto and M. Cervello: Antitumor effects of DHMEQ, a novel NF- $\kappa$ B inhibitor, in human liver cancer cells is mediated through a reactive oxygen species-dependent mechanism. *Molecular Pharmacology* 76:290-300, 2009.
307. M. Morioka, A. Kamizono, H. Takikawa, A. Mori, H. Ueno, S. Kadowaki, Y.

Nakao, K. Kato and K. Umezawa: Design, synthesis, and biological evaluation of novel estradiol-bisphosphonate conjugates as bone-specific estrogens. *Bioorg. Med. Chem.* 11:1143-1148, 2010.

308. M. Kawakami, A. Hirayama, K. Tsuchiya, H. Ohgawara, M. Nakamura, and K. Umezawa: Promotion of  $\beta$ -cell differentiation by the alkaloid conophylline in porcine pancreatic endocrine cells. *Biomedicine & Pharmacotherapy* 64: 226–231, 2010.

309. M. Takeuchi, S. Kimura, J. Kuroda, E. Ashihara, M. Kawatani, H. Osada, K. Umezawa, E. Yasui, M. Imoto, T. Tsuruo, A. Yokota, R. Tanaka, R. Nagao, T. Nakahata, Y. Fujiyama and T. Maekawa: Glyoxalase-I is a novel target against Bcr-Abl<sup>+</sup> leukemic cells acquiring stem-like characteristics in hypoxic environment. *Cell Death Diff.* 2010: 1-10, 2010.

310. K. Kodaira, E. Kikuchi, M. Kosugi, Y. Horiguchi, K. Matsumoto, K. Kanai, E. Suzuki, A. Miyajima, K. Nakagawa, M. Tachibana, K. Umezawa and M. Oya: Potent cytotoxic effect of a novel nuclear factor-kappa B inhibitor on human bladder cancer cells producing various cytokines. *Urology* 75: 805-812, 2010.

311. M. Murohashi, K. Hinohara, M. Kuroda, T. Isagawa, S. Tsuji, S. Kobayashi, K. Umezawa, A. Tojo, H. Aburatani and N. Gotoh: Gene set enrichment analysis provides insight into novel signaling pathways in breast cancer stem cells. *British J. Cancer* 102: 206-212, 2010.

312. R. Dror, M. Lederman, K. Umezawa, V. Barak, J. Pe'er and I. Chowers: Characterizing the involvement of the nuclear factor-kappa B (NF $\kappa$ B) transcription factor in uveal melanoma. *Investigative Ophthalmology & Visual Science* 58: 1811-1816, 2010.

313. D. Iwata, N. Kitaichi, A. Ebihara, K. Iwabuchi, K. Yoshida, K. Namba, M. Ozaki, S. Ohno, K. Umezawa, K. Yamashita, S. Todo, S. Ishida and K. Onoé: Nuclear factor- $\kappa$ B inhibitor, dehydroxy methyl epoxyquinomicin ameliorates experimental autoimmune uveoretinitis (EAU) in mice. *Investigative Ophthalmology & Visual Science* 51: 2077-2084, 2010.

314. C. Shimada, Y. Ninomiya, E. Suzuki and K. Umezawa: Efficient cellular uptake of

the novel NF- $\kappa$ B inhibitor (-)-DHMEQ and irreversible inhibition of NF- $\kappa$ B in neoplastic cells. *Oncology Research*, 18: 529-535, 2010.

315. A. Miyake, T. Ishida, M. Yamagishi, T. Hara, K. Umezawa, T. Watanabe and R. Horie: Inhibition of active HIV-1 replication by NF- $\kappa$ B inhibitor DHMEQ. *Microbes and Infection* 12: 400-408, 2010.

316. A. Hamasaka, N. Yoshioka, R. Abe, S. Kishino, K. Umezawa, M. Ozaki, S. Todo and H. Shimizu: Topical application of DHMEQ improves allergic inflammation via NF- $\kappa$ B inhibition. *Journal of Allergy and Clinical Immunology* 126: 400-403, 2010.

317. M. Hamada, T. Higashi, M. Shoji, K. Umezawa and T. Sugai: Lipase-catalyzed enantio- and regioselective transformation of 3-epi-shikimic acid derivatives as the key step for the entry of polyoxygenated carbacycles. *Journal of Molecular Catalysis B: Enzymic* 67: 78-84, 2010.

318. M. Hamada, Y. Niitsu, C. Hiraoka, I. Kozawa, T. Higashi, M. Shoji, K. Umezawa, T. Sugai: Chemoenzymatic synthesis of (2S,3S,4S)-form, the physiologically active stereoisomer of dehydroxymethylepoxyquinomicin (DHMEQ), a potent inhibitor on NF- $\kappa$ B. *Tetrahedron* 66:7083-7087, 2010.

319. N. Miyanishi, Y. Suzuki, S. Simizu, Y. Kuwabara, K. Banno and K. Umezawa: Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion. *Biochem. Biophys. Res. Commun.* 403: 154-159, 2010.

320. V. Cardile, G. Frasca, M. Libra, S. Caggia, K. Umezawa, A. Panico and G. Malaponte: Dehydroxymethylepoxyquinomicin inhibits expression and production of inflammatory mediators in interleukin-1 $\beta$ -induced human chondrocytes. *Cellular Physiology and Biochemistry* 25: 543-550, 2010.

321. T. Takahashi, S. Matsumoto, M. Matsushita, H. Kamachi, Y. Tsuruga, H. Kasai, M. Watanabe, M. Ozaki, H. Furukawa, K. Umezawa and S. Todo. Donor pretreatment with DHMEQ improves islet transplantation. *Journal of Surgical Research* 163: e23-34, 2010.

322. E. Suzuki, T. R. Daniels, G. Helguera, M. L. Penichet, K. Umezawa and B.



Bonavida: Inhibition of NF- $\kappa$ B and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis. *International J. Oncology* 36: 1299-1307, 2010.

323. T. Saitoh, C. Shimada, M. Takeiri, M. Shiino, S. Ohba, R. Obata, Y. Ishikawa, K. Umezawa and S. Nishiyama: A novel NF- $\kappa$ B inhibitor based on the amino-epoxyquinol core of DHMEQ. *Bioorg. Med. Chem. Lett.* 20: 5638-5642, 2010.

324. V. Cardile, M. Libra, S. Caggia, G. Frasca, K. Umezawa, F. Stivala, M. C. Mazzarino, Y. Bevelacqua, M. Coco and G. Malaponte: Dehydroxyquinomicin, a novel NF-kappa B inhibitor, prevents inflammatory injury induced by IFN- $\gamma$  and histamine in keratinocytes NCTC 2544. *Cellular and Experimental Pharmacology and Physiology* 37: 679-683, 2010.

325. K. Shinoda, K. Nakagawa, T. Kosaka, N. Tanaka, T. Maeda, H. Kono, R. Mizuno, E. Kikuchi, A. Miyajima, K. Umezawa, M. Oya: Regulation of human dendritic cells by a novel specific nuclear factor- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin. *Human Immunology* 71: 763-770, 2010.

326. L. Levati, F. Ruffini, A. Muzi, K. Umezawa, G. Graziani, S. D'Atri, P. M. Lacial: Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF- $\kappa$ B. *International J. Oncol.* 38: 241-247, 2011.

327. K. Mino, M. Ozaki, K. Nakanishi, S. Haga, M. Sato, M. Kina, M. Takahashi, N. Takahashi, A. Kataoka, K. Yanagihara, T. Ochiya, T. Kamiyama, K. Umezawa and S. Todo: Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. *Cancer Science* 102: 1052-1058, 2011.

328. K. Kobayashi, K. Umezawa and M. Yasui: Apoptosis in mouse amniotic epithelium is induced by activated macrophages through the TNF receptor type 1/TNF pathway. *Biology of Reproduction* 84: 248-254, 2011.

330. Y. Niitsu, M. Hakamata, Y. Goto, T. Higashi, M. Shoji, T. Sugai and K. Umezawa: Chemoenzymatic synthesis of (2*R*,3*R*,4*R*)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2. *Org. Biomol. Chem.*

9: 4635-4641, 2011.

331. K. Umezawa: Possible role of peritoneal NF- $\kappa$ B in peripheral inflammation and cancer: Lessons from the inhibitor DHMEQ. *Biomedicine & Pharmacotherapy* 65: 252-259, 2011.

332. H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa and S. Kobayashi: Synthesis and determination of the relative structure of akaterpin, a potent inhibitor of PI-PLC. *Tetrahedron Letters* 52: 4961-4964, 2011.

333. V. Rapozzi, K. Umezawa and L. E. Xodo: Role of NF- $\kappa$ B/Snail/RKIP loop in the response of tumor cells to photodynamic therapy. *Lasers in Surgery and Medicine* 43: 575–585, 2011.

334. M. Isshiki, K. Umezawa and H. Tamura: Coffee induces breast cancer resistance protein expression in Caco-2 cells. *Biol. Pharm. Bull.* 34: 1624-1627, 2011.

335. E. Suzuki, S. Yamashita and K. Umezawa: Role of NF- $\kappa$ B in thyroid cancer. In A. Carpi and J. L. Mechanick eds. "Thyroid Cancer, from Emergent Biotechnologies to Clinical Practice Guidelines" CRC Press, pp 319-327, 2011.

336. T. Saitoh, M. Takeiri, Y. Gotoh, Y. Ishikawa, K. Umezawa and S. Nishiyama: Design and synthesis of biotinylated DHMEQ for direct identification of its target NF- $\kappa$ B components. *Bioorganic & Medicinal Chemistry Letters* 21: 6293–6296, 2011.

337. K. Tsumura, A. Suzuki, T. Tsuzuki, H. Kaneko, S. Matsumura, M. Imoto, K. Umezawa, D. Takahashi and K. Toshima: Molecular design, chemical synthesis, and biological evaluation of agents that selectively photo-degrade the transcription factor estrogen receptor- $\alpha$ . *Org. Biomol. Chem.* 9: 6357-6366, 2011.

338. M. Takeiri, M. Tachibana, A. Kaneda, A. Ito, Y. Ishikawa, S. Nishiyama, R. Goto, K. Yamashita, S. Shibasaki, G. Hirokata, M. Ozaki, S. Todo and K. Umezawa: Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. *Inflammation Research* 60: 879-888, 2011.

339. T. Kubota and K. Umezawa: Suppression of erosive arthritis by NF- $\kappa$ B Inhibitors. *Current Rheumatology Reviews* 7: 275-281, 2011.
340. E. Ota, M. Takeiri, M. Tachibana, Y. Ishikawa, K. Umezawa and S. Nishiyama: Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide. *Bioorganic & Medicinal Chemistry Letters* 22:164-167, 2012.
341. T. Fukushima, M. Kawaguchi, K. Yorita, H. Tanaka, K. Umezawa, H. Kataoka: Antitumor effect of dehydroxymethylepoxyquinomicin (DHMEQ), a small molecule inhibitor of nuclear factor- $\kappa$ B, on glioblastoma. *Neuro-Oncology* 14: 19-28, 2012.
342. H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa and S. Kobayashi: Determination of the absolute structure of (+)-akaterpin. *Chem. Pharm. Bull.* 60:137-143, 2012
343. T. Funakoshi, K. Yamashita, N. Ichikawa, M. Fukai, T. Suzuki, R. Goto, T. Oura, N. Kobayashi, T. Katsurada, S. Ichihara, M. Ozaki, K. Umezawa, and Satoru Todo: A novel NF- $\kappa$ B inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. *Journal of Crohn's and Colitis*, in press.
344. C. Alberti, P. Pinciroli, B. Valeri, R. Ferri, A. Ditto, K. Umezawa, M. L. Sensi, S. Canevari, and A. Tomassetti: Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via NF $\kappa$ B pathway on advanced-stage epithelial ovarian cancer. *Oncogene*, in press.
346. M. Kawata, D. Koinuma, T. Ogami, K. Umezawa, C. Iwata, T. Watabe and K. Miyazono: TGF- $\beta$ -induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by proinflammatory cytokines derived from RAW 264.7 macrophage cells. *J. Biochem.*, in press.
347. R. Saito, S. Yamada, Y. Yamamoto, T. Kodera, A. Hara, Y. Tanaka, F. Kimura, I. Takei, K. Umezawa and I. Kojima: Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. *Endocrinology*, in press.
348. J. A. McCubrey, S. L. Abrams, K. Umezawa, L. Cocco, A. M. Martelli, R. A. Franklin, W. H. Chappell, L. S. Steelman: Novel approaches to target cancer initiating

cells—Eliminating the root of the cancer. *Advances in Enzyme Regulation*, in press.

349. R. Goto, K. Yamashita, T. Aoyagi, S. Ueki, M. Uno, T. Oura, N. Kobayashi, R. Igarashi, S. Shibasaki, K. Wakayama, G. Hirokata, T. Shibata, K. Umezawa, M. Ozaki, and S. Todo: The immunomodulatory effect of nuclear factor- $\kappa$ B inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion. *Transplantation*, in press.

350. M. Takeiri, E. Ota, S. Nishiyama, H. Kiyota, S. Simizu and K. Umezawa: Structure-activity relationship Of 9-methylstreptimidone that induces selective apoptosis in adult T-cell leukemia cells. *Oncology Res.*, in press.

351. M. Takeiri, K. Horie, D. Takahashi, M. Watanabe, R. Horie, S. Simizu and K. Umezawa: Involvement of DNA binding domain in the cellular stability and importin affinity of NF- $\kappa$ B component RelB. *Org. Biomol. Chem.*, in press.

352. N. Lampiasi, A. Azzolina<sup>1</sup>, K. Umezawa, G. Montalto, J. A. McCubrey and M. Cervello: The novel NF- $\kappa$ B inhibitor DHMEQ synergizes with Celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. *Cancer Lett.*, in press.

353. A. M. Castro-Gamero, K. S. Borgesa, V. da Silva Silveira, R. C. P. Lira, R. de Paula G. Queiroz, F. C. P. Valera, C. A. Scrideli, K. Umezawa and L. G. Tone: Inhibition of nuclear factor- $\kappa$ B by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. *Anti-Cancer Drugs*, in press.

354. K. Hinohara, S. Kobayashi, S. Simizu, K. Tada, E. Tsuji, K. Nishioka, K. Umezawa, M. Mori, H. Kanauchi, T. Ogawa, J. Inoue, A. T and N. Gotoh: ErbB/NF $\kappa$ B signaling controls self-renewal of breast cancer stem cells. *Proc. Natl. Acad. Sci. USA*, in press.